Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

During the Trading Day
53.48 +0.59 / +1.12%
As of 4:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
53.48 0.00 / 0.00%
Volume: 145.2K
3 Biotech Stocks to Buy in a Market Crash
9:24pm / MotleyFool.com
Why is Gilead (GILD) Stock Falling Today?
Jan 29 / Zacks.com
Play Strong Defense With 3 Big Biotechs
Feb 07 / TheStreet.com
Roche's (RHHBY) Earnings Miss Estimates, Revenues Beat
Jan 29 / Zacks.com
Is Gilead Sciences Finally Nearing a Bottom?
Feb 07 / MotleyFool.com
AbbVie Posts In-Line Earnings, Maintains 2016 Outlook
Jan 29 / Zacks.com
Rx for Success: Play Defense With Big Biotech
Feb 07 / TheStreet.com
Can Gilead (GILD) Keep the Earnings Streak Alive in Q4?
Jan 29 / Zacks.com
1 Company Gilead Sciences Should Consider Buying Right Now
Feb 06 / MotleyFool.com
Merck launches hepatitis C drug price war
Jan 29 / FT.com
Why Halozyme Therapeutics Inc Plunged 51% in January
Feb 06 / MotleyFool.com
Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space?
Jan 29 / MotleyFool.com
Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?
Feb 05 / MotleyFool.com
Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon
Jan 29 / MotleyFool.com
Stocks Continue to Sink
Feb 05 / TheStreet.com
AbbVie's (ABBV) 4Q Earnings In-Line With Estimates
Jan 29 / Zacks.com
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink
Feb 04 / Zacks.com
Why Incyte's Shares Crashed 12% Today
Jan 28 / MotleyFool.com
Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
Feb 03 / Zacks.com
3 Things to Watch in Gilead Sciences' Q4 Results
Jan 28 / MotleyFool.com
Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
Feb 03 / Zacks.com
Will AbbVie (ABBV) Keep the Earnings Streak Alive in Q4?
Jan 27 / Zacks.com
Why Regeneron Pharmaceuticals Shares Fell 23% in January
Feb 02 / MotleyFool.com
Will Currency Volatility Keep Hurting Abbott's (ABT) Earnings?
Jan 27 / Zacks.com
Why Gilead Sciences Shares Tumbled 18% in January
Feb 02 / MotleyFool.com
Amgen's Biosimilar of AbbVie's Humira under FDA Review
Jan 27 / Zacks.com
Gilead risks becoming victim of its own success
Jan 31 / FT.com
J&J investors urge activists to press for shake-up
Jan 27 / FT.com
Forget Biosimilars: It's This Threat That Could Dent AbbVie's Top Line
Jan 31 / MotleyFool.com
Global pharma groups reveal tie-up with universities
Jan 24 / FT.com
AbbVie: There Ain't No Stinkin' Biosimilar Threat
Jan 30 / MotleyFool.com
Shire deal demonstrates Kilsby's M&A acumen
Jan 15 / FT.com
Here's Why Johnson & Johnson's Sales Fell Last Year
Jan 30 / MotleyFool.com
Shire agrees $32bn takeover of Baxalta
Jan 11 / FT.com
Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price
Jan 29 / Zacks.com